| | Starting Dose | Frequency | Notes | | :--- | :--- | :--- | :--- | | Weeks 1–4 | 0.25 mg | Once weekly | Initial loading dose; not effective for blood sugar control alone. | | Weeks 5–8 | 0.5 mg | Once weekly | Therapeutic dose for glycemic control. | | Week 9+ | 1.0 mg | Once weekly | Standard maintenance dose if additional control is needed. | | If still needed | 2.0 mg | Once weekly | Maximum approved dose for T2D (some patients remain on 1 mg). |
| | Starting Dose | Frequency | Notes | | :--- | :--- | :--- | :--- | | Weeks 1–4 | 0.25 mg | Once weekly | Initial loading dose; not effective for blood sugar control alone. | | Weeks 5–8 | 0.5 mg | Once weekly | Therapeutic dose for glycemic control. | | Week 9+ | 1.0 mg | Once weekly | Standard maintenance dose if additional control is needed. | | If still needed | 2.0 mg | Once weekly | Maximum approved dose for T2D (some patients remain on 1 mg). |
(1) Roll of ISO 8502-3 Tape for use with PosiTest DT test—25 mm wide
Replacement dust tape comparator, transparent display board, and (4) 25 pack of Report Forms
